Leukapheresis Products Market Analysis (2023 to 2033)
The leukapheresis products market is estimated to secure a valuation of US$ 1.2 billion in 2023 and is estimated to rise to US$ 2.1 billion by 2033. According to Future Market Insights, the market is anticipated at a CAGR of 5.7% during the forecast period. The factors accelerating the demand for leukapheresis products are as follows-
Increasing incidences and prevalence of leukemia
Advances in medical technology and research science
Increases demand for leukopaks in clinical research
Increased number of patients suffering from the blood-related disorder
Increased cases of Cancer worldwide
Growing geriatric population
Increasing demand for blood donation
Increasing CAR T-cell therapy clinical trials
North America dominates the leukapheresis products market during the forecast period
Data Points
Key Statistics
Expected Market Value of Leukapheresis Products in 2023
US$ 1.2 billion
Projected Market Value of Leukapheresis Products in 2033
US$ 2.1 billion
Growth Rate of the Leukapheresis Products Market from 2023 to 2033
CAGR of 5.7%
The growing number of blood-related disorders and the increased availability of favorable government initiatives along with reimbursement policies are expected to drive the leukapheresis products market during the forecast period. Also, the growing popularity of blood donation and the increased number of blood transfusion services are likely to drive market growth.
The increasing prevalence of chronic diseases such as cancer and autoimmune diseases is expected to boost the leukapheresis products market. Leukapheresis is used in cancer treatment to remove the leukemic cell from the blood. Thus the increased number of cancer cases worldwide is fuelling the market demand.
Increased government investments in R&D activities abode well for market growth. The leukapheresis products are majorly used in research & therapeutics applications.
North America acquires the highest share of the leukapheresis products market during the forecast period. the factors driving the market growth in the region include increased cases of leukemia, the presence of well-developed healthcare infrasture, and growing government initiatives.
Europe is expected to account for the second highest share in the leukapheresis market due to the increasing advances in medical technology and increased prevalence of blood-related disorders in the region
Asia Pacific is expected to provide a lucrative opportunity for the growth of the leukapheresis products market during the forecast period. The increasing prevalence of chronic diseases and other disorders in the region is likely to drive the leukapheresis products market.
The leading player operating the leukapheresis products market are Haemonetics, Frost & Sullivan, Fresenius SE & Co, KGaA, Asahi Kasei Medical Co, Stem Express LLC, AllCells LLC, Cerus Corporation, Charles River Laboratories, Hemac Corporation, Terumo BCT Inc, fresinus Medical Care, Macopharma SA, Fresenius KB among others.
The key players in the leukapheresis products market are using different strategies like mergers, acquisitions, and partnerships to increase their brand presence. Also, the leading players are focusing on innovation to develop innovative leukapheresis products. Some of the developments from the market are listed below.
For instance, in March 2023- Harmonetics Corporation announced the next generation of Intelligent control software for cell server Elite and autotransfusion service.
In June 2022- Asahi Kasei Medical completed the acquisition of Bionova Scientific LLC, a USA-based biopharmaceutical CDMO.
The demand for leukapheresis products is expected to flourish during the forecast period owing to the increasing incidences of chronic diseases and rising demand for blood & blood products. Start-ups are entering the leukapheresis products market with innovative products to fulfill the increased demand for the product.
For instance, in 2000 Intercept blood system is the developer of blood transfusion and the company’s products include the intercept blood system, which is a single pathogen inactive system for platelets/plasma used for the reduction of transfusion-transmitted infection.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Leukapheresis Products Market Overview
Leukapheresis is the treatment of Leukaemia to reduce the WBC count in the patient’s body. Globally there is a significant increase in the incidence and prevalence of leukaemia, in 2019, as per the Leukaemia and Lymphoma Society (LLS), more than 61,000 patients were diagnosed with leukaemia.
The leukapheresis products market is expected to grow at a good pace due to the prevalence of the disease at a good CAGR during the forecast period (2021 to 2031).
What is Driving Demand for Leukapheresis Products Market?
Major drivers of the Leukapheresis products market are an increased number of blood donations, increased initiatives by key players in the leukapheresis market’s field, and frequent advancement in medical technology and Research sciences. The Leukapheresis products market is expected to grow at an explosive CAGR during the forecast period of 2023 to 2033.
One of the best examples of demand drivers of sales of leukapheresis products is the production and excessive sales of “Leukopaks”, which are enriched with high concentrations of lymphocytes containing leukapheresis products.
Find your sweet spots for generating winning opportunities in this market.
What is the Repercussion of the Pandemic on the Growth of the Leukapheresis Products Market?
According to a detailed analysis, the pandemic should have a big positive impact on the leukapheresis market since a lot of clinical trials were done widely for COVID-19 vaccines. NIH is also conducting trials that have a requirement of leukapheresis for understanding the effects of SARS-CoV-2 on WBCs.
In the year 2021, it was observed that exponential growth was observed as per the factual statistics done by WHO, so there is a huge possibility that this market is going to face a big profit during the forecast period.
The USA and Canada Leukapheresis Products Market Outlook
The largest share in the Leukapheresis product market is held by the North American region (the USA and Canada), as a dominant percentage of the market share is occupied by North American Leukapheresis market. An increase in neurological disorders and blood-related disorders like “Leukemia” which are already very incident and prevalent in this region makes these disorders the major drivers of the given leukapheresis market.
According to a press release, by 2027 Leukapheresis product market is to surpass the sales with the boom blast growth when compared to 2020. In 2020, the leukapheresis product market exhibited a beautifully high CAGR or would exhibit an even more rate of growth during the forecast period (2021-2031).
Since the cost of Leukapheresis is very high it acts as a restraint on the Leukapheresis market in the end-user segment of hospitals and blood donation banks but the value of leukapheresis in the therapeutic and research sector is expected to gain pace.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Demand Outlook for Leukapheresis Products Europe market
The European region (majorly Germany, United Kingdom, Belgium, and Italy) occupies about a big chunk of the global leukapheresis market after the USA and Canada combined which makes it the second-largest primary participant in the global market.
The European market of leukapheresis products is predicted to show a good percentage of CAGR as per the forecasted period of 2023 to 2028 since technological and medical advancements are not only helping the market growth but also there’s a growth of the markets which are linked to the leukapheresis products market due to which the revenue collection in the end-use industries like hospitals and apheresis units is pretty well.
Who are the Key Manufacturers and Suppliers of Leukapheresis Products?
Some of the leading manufacturers and suppliers of Leukapheresis products include
Haemonetics Corporation
Frost and Sullivan
Fresenius SE & Co.
KGaA
Asahi Kasei Medical Co. Ltd.
StemExpress, LLC
AllCells, LLC
Cerus Corporation
Charles River Laboratories
Hemacare Corporation
Terumo BCT, Inc
Fresenius medical care
Macopharma SA.
Fresenius Kabi.
In 2020, a plasmapheresis treatment was provided to a COVID-19 using highly advanced medical equipment which was installed in the GMC, Kerala for the treatment of apheresis. This upgrade shows how the future of the leukapheresis market lies in the Asia Pacific region with an incredible CAGR percentage.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
